PYURF

Across TCGA pan-cancer cohorts, PYURF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PYURF data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PYURF mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PYURF expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where PYURF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.754	0.379	<.001	90	view →
UCEC	DFS	Median	II,III,IV	0.566	0.930	.025	8	view →
CCRCC	DFS	Quartile	All	1.000	0.531	.012	4	view →
LUAD	OS	Tertile	II,III,IV	0.687	0.268	.013	4	view →
GBM	DFS	Quartile	All	1.000	0.637	.035	1	view →
LSCC	DFS	Quartile	All	0.701	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PYURF–PDAC (OS)

Open the PDAC breakdown →